<DOC>
	<DOCNO>NCT00722566</DOCNO>
	<brief_summary>Randomized , open-label , international , multi-center , Phase 3 study patient randomize receive VELCADE administer subcutaneous injection intravenous infusion .</brief_summary>
	<brief_title>A Study Subcutaneous Intravenous VELCADE Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Male female subject 18 year old 2 . Diagnosis multiple myeloma 3 . Measurable , secretory multiple myeloma define serum monoclonal IgG ≥10 g/L , serum monoclonal IgA IgE ≥5 g/L , serum monoclonal IgD ≥0.5g/L ; urine Mprotein ≥200 mg/24 hr 4 . Relapse progression myeloma follow prior systemic antineoplastic therapy . 1 . Previous treatment VELCADE 2 . More 3 previous line therapy ( separate line therapy define single combination therapy either separated disease progression great 6 month treatmentfree interval ) 3 . Peripheral neuropathy neuropathic pain NCI CTCAE Grade ≥2 4 . Any follow within 3 week prior randomization : antineoplastic experimental therapy , corticosteroid use 10mg day ( prednisone equivalent ) , plasmapheresis 5 . Any follow within 2 week prior randomization : radiation therapy , major surgery ( kyphoplasty consider major surgery ) 6 . Prior malignancy multiple myeloma diagnose treat within last 2 year , exception completely resect carcinoma situ basal/squamous carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>